SCHEMBL2498488

SCHEMBL2498488

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2ccc(S(=O)(=O)CCCN3CCCC3)cc2)nc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 14/20 0.67
BTK Q06187 13/20 0.67
MAPK14 Q16539 5/20 0.67
KDR P35968 2/20 0.67
TEK Q02763 2/20 0.67
ABL1 P00519 1/20 0.67
FYN P06241 1/20 0.67
CSF1R P07333 1/20 0.67
LYN P07948 1/20 0.67
SRC P12931 1/20 0.67
MAPK9 P45984 1/20 0.67
BLK P51451 4/20 0.62
JAK3 P52333 2/20 0.60
EGFR P00533 1/20 0.59
ERBB2 P04626 1/20 0.59
TEC P42680 1/20 0.59
TXK P42681 1/20 0.59
BMX P51813 1/20 0.59
ERBB4 Q15303 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2496048 0.92 BTK (0.57) LCKBTKMAPK14KDRTEK
SCHEMBL2495540 0.91 BTK (0.61) LCKBTKMAPK14KDRTEK
SCHEMBL14286497 0.91 BTK (0.56) LCKBTKMAPK14KDRTEK
SCHEMBL2495019 0.86 LCK (0.70) LCKBTKMAPK14KDRTEK
SCHEMBL2493709 0.86 LCK (0.70) LCKBTKMAPK14KDRTEK
SCHEMBL2495538 0.84 SRC (0.48) LCKBTKMAPK14KDRTEK
SCHEMBL2496233 0.84 MEN1 (0.49) LCKBTKMAPK14KDRTEK
SCHEMBL2492307 0.84 LCK (0.74) LCKBTKMAPK14KDRTEK
SCHEMBL2498530 0.84 CSF1R (0.51) LCKBTKMAPK14KDRTEK
SCHEMBL12190169 0.83 LCK (0.68) LCKBTKMAPK14KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 LCK 9/4885BTK 44/4885MAPK14 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.